Cormorant Asset Management’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$854K Sell
15,000
-35,000
-70% -$2.04M 0.06% 59
2026
Q2
$2.91M Sell
50,000
-50,000
-50% -$2.72M 0.15% 48
2026
Q1
$5.81M Sell
100,000
-25,000
-20% -$1.36M 0.29% 44
2025
Q4
$5.77M Sell
125,000
-50,000
-29% -$2.24M 0.27% 33
2025
Q3
$6.3M Hold
175,000
– – 0.43% 34
2025
Q2
$5.69M Hold
175,000
– – 0.42% 36
2025
Q1
$6.61M Sell
175,000
-250,000
-59% -$20M 0.5% 35
2024
Q4
$34.8M Sell
425,000
-575,000
-58% -$57.1M 1.91% 14
2024
Q3
$114M Sell
1,000,000
-100,000
-9% -$9.01M 6.06% 2
2024
Q2
$83.1M Buy
1,100,000
+415,000
+61% +$28.2M 4.8% 4
2024
Q1
$46.8M Buy
685,000
+20,000
+3% +$1.38M 2.05% 14
2023
Q4
$41.8M Hold
665,000
– – 1.99% 14
2023
Q3
$33.9M Hold
665,000
– – 1.98% 13
2023
Q2
$33.2M Buy
665,000
+390,000
+142% +$18.5M 1.86% 11
2023
Q1
$10.3M Sell
275,000
-50,000
-15% -$2.12M 0.68% 38
2022
Q4
$15.6M Buy
+325,000
New +$12.8M 1.04% 31

Other funds holding PCVX

Cormorant Asset Management's PCVX Position: Q3 2026 in Review

Cormorant Asset Management reduced its Vaxcyte (PCVX) stake by 70% in Q3 2026, selling an estimated $2.04M and leaving 15,000 shares worth $854K. The position accounts for 0.06% of the portfolio, ranked #59.

Cormorant Asset Management first reported a position in PCVX in Q4 2022 and has held it in 16 quarters since. The position peaked at $114M in Q3 2024. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Cormorant Asset Management held 15,000 shares of Vaxcyte worth $854K as of Q3 2026.
  • Cormorant Asset Management sold 35,000 Vaxcyte shares in Q3 2026, an estimated $2.04M.
  • Vaxcyte made up 0.06% of Cormorant Asset Management's portfolio in Q3 2026, its #59 holding.
  • Cormorant Asset Management first reported a position in Vaxcyte in Q4 2022 and has held it in 16 quarters since.
  • Cormorant Asset Management's Vaxcyte position peaked at $114M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Cormorant Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.